Results for &quot;&quot;Receptor, Fibroblast Growth Factor, Type 1&quot;&quot;[mesh_terms]

Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.

R Bahleda, F Meric-Bernstam, L Goyal, B Tran, Y He, I Yamamiya, K A Benhadji, I Matos, H-T Arkenau

Annals of oncology : official journal of the European Society for Medical Oncology 2021;31(10):1405-1412

Thrifty energy phenotype predicts weight regain in postmenopausal women with overweight or obesity and is related to FGFR1 signaling.

Leonard Spranger, January Weiner, Josephine Bredow, Ulrike Zeitz, Ulrike Grittner, Michael Boschmann, Sophia Dickmann, Nicole Stobäus, Reiner Jumpertz-von Schwartzenberg, Maria Brachs, Joachim Spranger, Knut Mai

Clinical nutrition (Edinburgh, Scotland) 2023;42(4):559-567

FGF23 and the parathyroid glands.

Tally Naveh-Many, Justin Silver

Pediatric nephrology (Berlin, Germany) 2011;25(11):2241-5

Transcriptional insights into pathogenesis of cutaneous systemic sclerosis using pathway driven meta-analysis assisted by machine learning methods.

Xiao Xu, Meera Ramanujam, Sudha Visvanathan, Shervin Assassi, Zheng Liu, Li Li

PloS one 2021;15(11):e0242863

Anti-FGFR1 aptamer-tagged superparamagnetic conjugates for anticancer hyperthermia therapy.

Przemysław M Jurek, Konrad Zabłocki, Urszula Waśko, Maciej P Mazurek, Jacek Otlewski, Filip Jeleń

International journal of nanomedicine 2017;12():2941-2950

The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma.

Thai H Ho, Xian-De Liu, Yanqing Huang, Carla L Warneke, Marcella M Johnson, Anh Hoang, Pheroze Tamboli, Fen Wang, Eric Jonasch

BMC cancer 2016;15():304

A novel dominant-negative FGFR1 variant causes Hartsfield syndrome by deregulating RAS/ERK1/2 pathway.

Pietro Palumbo, Antonio Petracca, Roberto Maggi, Tommaso Biagini, Grazia Nardella, Michele Carmine Sacco, Elia Di Schiavi, Massimo Carella, Lucia Micale, Marco Castori

European journal of human genetics : EJHG 2020;27(7):1113-1120

t(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature.

Jad J Wakim, Carlos A Tirado, Weina Chen, Robert Collins

Leukemia research 2011;35(9):e151-3

Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer.

Juliann Chmielecki, Martin Peifer, Peilin Jia, Nicholas D Socci, Katherine Hutchinson, Agnes Viale, Zhongming Zhao, Roman K Thomas, William Pao

Nucleic acids research 2011;38(20):6985-96

Cell Type-specific Adaptive Signaling Responses to KRAS Inhibition.

Hitendra S Solanki, Eric A Welsh, Bin Fang, Victoria Izumi, Lancia Darville, Brandon Stone, Ryan Franzese, Sandip Chavan, Fumi Kinose, Denis Imbody, John M Koomen, Uwe Rix, Eric B Haura

Clinical cancer research : an official journal of the American Association for Cancer Research 2022;27(9):2533-2548

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.

Milind Javle, Sameek Roychowdhury, Robin Kate Kelley, Saeed Sadeghi, Teresa Macarulla, Karl Heinz Weiss, Dirk-Thomas Waldschmidt, Lipika Goyal, Ivan Borbath, Anthony El-Khoueiry, Mitesh J Borad, Wei Peng Yong, Philip A Philip, Michael Bitzer, Surbpong Tanasanvimon, Ai Li, Amit Pande, Harris S Soifer, Stacie Peacock Shepherd, Susan Moran, Andrew X Zhu, Tanios S Bekaii-Saab, Ghassan K Abou-Alfa

The lancet. Gastroenterology & hepatology 2021;6(10):803-815

Ligand-binding sites in Ig-like domains of receptor tyrosine kinases.

C Wiesmann, Y A Muller, A M de Vos

Journal of molecular medicine (Berlin, Germany) 2000;78(5):247-60

Tumour-induced osteomalacia.

Salvatore Minisola, Munro Peacock, Seijii Fukumoto, Cristiana Cipriani, Jessica Pepe, Sri Harsha Tella, Michael T Collins

Nature reviews. Disease primers 2018;3():17044

GPER Mediates a Feedforward FGF2/FGFR1 Paracrine Activation Coupling CAFs to Cancer Cells toward Breast Tumor Progression.

Maria Francesca Santolla, Adele Vivacqua, Rosamaria Lappano, Damiano Cosimo Rigiracciolo, Francesca Cirillo, Giulia Raffaella Galli, Marianna Talia, Giuseppe Brunetti, Anna Maria Miglietta, Antonino Belfiore, Marcello Maggiolini

Cells 2019;8(3):223